Compare MasTec Inc (MTZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MasTec Inc trades at $282.97 (market cap $21.90B), while State Street SPDR S&P Biotech ETF trades at $159.65. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| MTZ | XBI | |
|---|---|---|
Market Cap | $21.90B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $437.51 | $164.28 |
52-Week Low | $172.51 | $86.92 |
Enterprise Value | $24.81B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $283.76, up 5.77% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported record Q2 2026 revenue of $4.374 billion, up 23% year-over-year, and raised its full-year outlook. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show resistance near $283.
The outlook remains positive due to robust infrastructure demand, a record $21.4 billion backlog, and strategic acquisitions like The Superior Group. Risks include execution challenges in communications segments and high valuation multiples. Earnings growth and backlog execution are key catalysts for further upside.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
